New technology at John Theurer Cancer Center designed to target multiple tumors

The John Theurer Cancer Center at Hackensack University Medical Center will be the first in New Jersey and one of only five cancer programs – across the globe – to offer one of the most advanced radiation therapy systems to treat patients with cancer. The RefleXion®X1 is the world’s first machine to deliver biologically-guided radiotherapy (BgRT*) that can improve treatment and expand options for patients with metastatic disease, where few treatments are currently available.

RefleXion’s BgRT, under review with the US Food and Drug Administration, which you can see here, combines PET imaging with stereotactic radiotherapy to allow doctors to detect and respond to signals emitted by the cancer itself and for the first time t ‘use them to guide. immediate treatment.

“This is truly a game changer in cancer treatment, and we are very pleased to offer this to our patients in the future, even in some of our most challenging cases,” said Mark D. Sparta, FACHE, President and Chief Executive Officer of the Hospital. Hackensack University Medical Center and President, North Region, Hackensack Meridian health. “This technology is so precise, it targets the tumor and can allow a higher dose of radiation to be focused on cancer cells while shielding healthier tissue from the radiation. Investing in an advanced technology like this reaffirms our commitment to providing our patients with the most advanced technology available worldwide.”

“The key differentiator with RefleXion’s biology-directed radiotherapy is the continuous direct response from the tumor itself,” said Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center at Hackensack University Medical Center. “Real-time BgRT is designed to enable the delivery of a tracked dose of radiation to multiple tumors in the same session while making the tumors themselves continuously signal their location, it’s incredible.”

As patients move, so do tumors. Even breathing, bending, or involuntary muscle movement can change the location of a tumor. To account for this tumor motion, current radiotherapy methods require that the entire envelope of tumor motion and uncertainty—known as the internal target volume (ITV)—be targeted for radiation.

By tracking the distribution of radiation dose to cancer cells when radiotherapy is delivered – like a tumor-following spotlight – BgRT is designed to eliminate the need to deliver radiation throughout the ITV. Therefore, more healthy tissue in the surrounding organ is spared from injury, resulting in less toxicity to the patient. In turn, this may allow a higher dose to be delivered to the target tumor or may allow a portion of the radiation dose to be delivered elsewhere at the site of another tumor.

“It’s a more sophisticated and effective treatment option,” says Chief of Radiation Oncology Adnan Danish, attending physician at Hackensack Meridian John Theurer Cancer Center and Chief of Radiation Oncology at St. Joseph, in partnership with Hackensack Meridian . “BgRT is a departure from current technology, which has required each individual tumor to have its own complex solution for managing motion and uncertainty. Because of this complexity, going beyond some tumors has not been feasible in most cases.”

RefleXion X1 is currently approved for the treatment of patients using conventional stereotactic body radiotherapy, intensity modulated radiation therapy and stereotactic radiosurgery. The BgRT feature is expected to receive approval from the US Food and Drug Administration in 2022. The system will be installed at Hackensack University Medical Center in the fall of 2022.

Leave a Comment

Your email address will not be published.